

# Kausik Umanath

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9067447/publications.pdf>

Version: 2024-02-01

30  
papers

1,388  
citations

686830

13  
h-index

525886

27  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1667  
citing authors

#	ARTICLE	IF	CITATIONS
1	Update on Diabetic Nephropathy: Core Curriculum 2018. American Journal of Kidney Diseases, 2018, 71, 884-895.	2.1	550
2	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney International, 2021, 100, 215-224.	2.6	182
3	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation, 2020, 35, 1700-1711.	0.4	107
4	Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). American Journal of Kidney Diseases, 2018, 71, 352-361.	2.1	104
5	Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. Journal of the American Society of Nephrology: JASN, 2015, 26, 2578-2587.	3.0	88
6	Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. Journal of the American Society of Hypertension, 2016, 10, 847-856.	2.3	56
7	The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. American Journal of Kidney Diseases, 2015, 66, 479-488.	2.1	41
8	Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Tj ETQq0 0 0 rgBT /Overlock, 10 Tf 50 462 Td (No (Irbesartan Diabetic Nephropathy Trial)). American Journal of Kidney Diseases, 2015, 66, 450-458.	2.1	37
9	Pyridoxamine Dihydrochloride in Diabetic Nephropathy (PIONEER-CSG-17): Lessons Learned from a Pilot Study. Nephron, 2015, 129, 22-28.	0.9	30
10	High SARS-CoV-2 Viral Load in Urine Sediment Correlates with Acute Kidney Injury and Poor COVID-19 Outcome. Journal of the American Society of Nephrology: JASN, 2021, 32, 2517-2528.	3.0	30
11	Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 545-550.	0.7	22
12	Self-Motivation Is Associated With Phosphorus Control in End-Stage Renal Disease. , 2015, 25, 433-439.		21
13	Rationale and study design of a threeâ€period, 58â€week trial of ferric citrate as a phosphate binder in patients with <scp>ESRD</scp> on dialysis. Hemodialysis International, 2013, 17, 67-74.	0.4	20
14	Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy. CKJ: Clinical Kidney Journal, 2014, 7, 53-56.	1.4	18
15	Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data. Drugs in R and D, 2015, 15, 271-279.	1.1	12
16	Health care providersâ€™ support of patientsâ€™ autonomy, phosphate medication adherence, race and gender in end stage renal disease. Journal of Behavioral Medicine, 2016, 39, 1104-1114.	1.1	12
17	Diabetic Kidney Disease: The Tiger May Have New Stripes. American Journal of Kidney Diseases, 2018, 72, 631-633.	2.1	9
18	Pharmacological Effects of Exâ€™%oVivo Mesenchymal Stem Cell Immunotherapy in Patients with Acute Kidney Injury and Underlying Systemic Inflammation. Stem Cells Translational Medicine, 2021, 10, 1588-1601.	1.6	9

#	ARTICLE	IF	CITATIONS
19	Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience. <i>Journal of Cardiac Failure</i> , 2022, 28, 21-31.	0.7	8
20	The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis. <i>Clinical Nephrology</i> , 2017, 87, 124-133.	0.4	6
21	Ferric citrate: a novel phosphate-binding agent. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 13-19.	1.2	5
22	In-Center Thrombolysis for Clotted AV Access: A Cohort Review. <i>Seminars in Dialysis</i> , 2013, 26, 124-129.	0.7	4
23	Optimizing Blood Pressure Control in Patients With Nondiabetic Glomerular Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 200-204.	0.6	4
24	Getting to the Heart of the Matter: Review of Treatment of Cardiorenal Syndrome. <i>Advances in Chronic Kidney Disease</i> , 2017, 24, 261-266.	0.6	4
25	Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis. <i>Hemodialysis International</i> , 2017, 21, 243-249.	0.4	4
26	Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 705-710.	1.3	2
27	Guidelines and Straitjackets: Blood Pressure Targets in the Era of the Eighth Joint National Committee. <i>American Journal of Kidney Diseases</i> , 2014, 63, 895-899.	2.1	2
28	Hypertension: A Common but Complex Condition. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 85-86.	0.6	1
29	FP590FERRIC CITRATE (FC) AS A PHOSPHATE BINDER IN PERITONEAL DIALYSIS (PD). <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii270-iii270.	0.4	0
30	Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials. <i>Clinical Investigation</i> , 2015, 5, 551-559.	0.0	0